LifeVantage Corp. (LFVN) - Q3 2026 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly report on Form 10-Q for LifeVantage Corp. for the period ended March 31, 2026. LifeVantage is a nutrigenomics company operating a direct sales model globally, selling dietary supplements, personal care products, and nootropics through a network of independent consultants. The company operates as a single reporting segment.
Key Financial Metrics
| Metric | Q3 2026 (3 Months) | Q3 2025 (3 Months) | YTD 2026 (9 Months) | YTD 2025 (9 Months) |
|---|---|---|---|---|
| Net Revenue | $43.7 million | $58.4 million | $140.2 million | $173.4 million |
| Gross Profit | $34.5 million | $47.3 million | $108.6 million | $139.6 million |
| Gross Margin | 79.0% | 81.0% | 77.4% | 80.5% |
| Operating Income | $1.7 million | $4.1 million | $4.4 million | $10.1 million |
| Net Income | $1.4 million | $3.5 million | $3.8 million | $7.8 million |
| Diluted EPS | $0.11 | $0.26 | $0.30 | $0.60 |
| Cash & Equivalents | $12.5 million | $20.2 million (Jun 2025) | N/A | |
| Working Capital | $19.2 million | $23.7 million (Jun 2025) | N/A | |
| Debt Outstanding | $0 | $0 | N/A |
Material Changes vs. Prior Period
- Revenue Decline: Net revenue decreased 25.2% year-over-year for the quarter and 19.2% year-over-year for the nine-month period. The primary driver was a significant decline in sales of the MindBody GLP-1 System, which dropped $9.6 million in the quarter and $20.1 million YTD.
- Active Accounts Contraction: Total active accounts (consultants and customers) fell 22.1% to 109,000. Active independent consultants decreased 13.5% to 45,000, while active customers dropped 27.3% to 64,000.
- Geographic Performance: The Americas region saw a 28.9% revenue decline, heavily impacted by the US market (-30.1%). The Asia/Pacific & Europe region declined 7.7%, with Japan down 10.0%.
- Acquisition Impact: The company acquired LoveBiome in October 2025. While LoveBiome contributed $3.2 million in revenue for the quarter, it did not fully offset the decline in legacy product lines.
- Inventory Obsolescence: Gross margin compression was driven by a $2.6 million charge for inventory obsolescence related to the MindBody GLP-1 System during the nine-month period.
Guidance, Outlook, and Risks
- Capital Allocation: The company continues to return capital to shareholders, paying $1.7 million in dividends YTD and repurchasing $1.6 million of stock. A new $60 million stock repurchase program was approved in January 2026, with $59 million remaining as of March 31, 2026.
- Liquidity: Cash and cash equivalents decreased by $7.7 million to $12.5 million. The company maintains a $5.0 million revolving credit facility with Bank of America, which currently has no outstanding balance.
- Strategic Focus: Management is focusing on refining product offerings internationally and strengthening the core business. New product stacks combining Protandim, MindBody GLP-1, and LoveBiome products have been introduced.
- Risks: Key risks include the continued decline in active accounts, dependence on a few key products (Protandim, TrueScience, LifeVantage), and the ability to manage inventory levels effectively. The filing notes that actual results may differ materially from forward-looking statements due to market conditions and regulatory changes.
Investor Verification Checklist
- Inventory Valuation: Verify the $2.6 million inventory obsolescence charge and assess if further write-downs are necessary for the MindBody GLP-1 System.
- Consultant Retention: Monitor the trend of active independent consultants, which has declined for two consecutive quarters, to gauge the health of the direct sales model.
- LoveBiome Integration: Track the revenue contribution and profitability of the LoveBiome acquisition to determine if it can offset legacy product declines.
- Cash Burn Rate: Review the $7.7 million decrease in cash against operating cash flow ($5.5 million YTD) to ensure sufficient liquidity for operations and dividend payments.
- Debt Covenants: Confirm continued compliance with the 2024 Credit Facility covenants, particularly given the reduction in operating income.